[1] Heel RC, et al. Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs. 1979;17(6):425-460. DOI:
10.2165/00003495-197917060-00001[2] Engel G, et al. (+/-)[125Iodo] cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. Naunyn Schmiedebergs Arch Pharmacol. 1981;317(4):277-285. DOI:
10.1007/BF00501307[3] Corsini A, et al. Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol Res. 1993 May-Jun;27(4):299-307. DOI:
10.1006/phrs.1993.1030[4] Lorusso B, et al. Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro. Vascul Pharmacol. 2022 Oct;146:107110 DOI:
10.1016/j.vph.2022.107110[5] Shen FM, et al. Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats. Acta Pharmacol Sin. 2005 Nov;26(11):1303-8. DOI:
10.1111/j.1745-7254.2005.00185.x[6] Gould S, et al. Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst. 2007 Nov 21;99(22):1724-8. DOI:
10.1093/jnci/djm202[7] Horinouchi T, et al. Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. DOI:
10.1016/j.lfs.2007.06.003 
